Acute and Late Toxicity In Breast Cancer Patient That Received Hypofractionated Adjuvant Radiotherapy after Breast Conserving Surgery: A Case Report

Sinta Prastiana Dewi, Henry Kodrat

Abstract


Introduction: Breast cancer is the most common female malignancy worldwide. Breastconserving surgery followed by adjuvant radiotherapy is a preferable treatment option. Hypofractionated radiotherapy is an attractive fractionation scheme because of its shorter treatment duration. This paper aims to report the short-term and long-term toxicity of hypofractionated radiotherapy in breast cancer patients at our institution. Case Presentation: A 58-year-old woman with right breast cancer T2N1M0 had undergone breast-conserving surgery with axilla lymph node dissection. This patient underwent adjuvant whole breast radiotherapy with a dose of 42.56 Gy in 16 fractions followed by tumor bed boost with a dose of 16 Gy in 8 fractions. After undergoing the fourth fraction of boost, she had hyperpigmentation on her radiation area (RTOG skin toxicity grade 1). At the 6-month follow-up, the hyperpigmentation still appeared. Until the 24-month follow-up, after she completed radiotherapy, there was no sign of tumor recurrence and toxicity.

Conclusion: Hypofractionated radiotherapy could be an option for breast cancer treatment that provides equivalent local control, survival, and side effects to conventional fractionation radiotherapy.


Keywords


breast cancer, hypofractionated, radiotherapy, toxicity

References


Kementrian Kesehatan RI. Buletin Jendela Data & Informasi Kesehatan: Situasi penyakit kanker [Internet]. 2015 [cited 2020 Jun 29]. Available from: https://pusdatin.kemkes.go.id/download.php?file=download/pusdatin/buletin/Buletin-SIK-2016.pdf.

International Agency for Research on Cancer. Cancer Today [Internet]. 2018 [cited 2020 Jun 29]. Available from: https://gco.iarc.fr/today/online-analysis-piev=2018&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0&population_group_globocan_id=

Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.

Qi XS, White J, Li XA. Is α/β for breast cancer really low? Radiother Oncol. 2011;100(2):282–8.

Holloway CL, Panet-Raymond V, Olivotto I. Hypofractionation should be the new “standard” for radiation therapy after breast conserving surgery. Breast. 2010;19(3):163–7.

Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast : Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8(3):145-52.

Cox JD, Stetz JA, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.

Stuckey A. Breast Cancer. Clin Obstet Gynecol. 2011;54(1):96–102.

Agrawal RK, Aird EGA, Barrett JM, et al. A The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;9:331–41.

Agrawal RK, Aird EGA, Barrett JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–107.

Whelan TJ, Pignol J-P, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.

Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.

Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-Year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259–65.

Karasawa K, Banu AP, Tasbolat A, et al. A prospective international study on safety and efficacy of hypofractionated radiation therapy for post-operative breast cancer patients in asian countries. Int J Radiat Oncol. 2018;102(3):e577.

Osako T, Oguchi M, Kumada M, et al. Acute radiation dermatitis and pneumonitis in japanese breast cancer patients with whole breast hypofractionated radiotherapy compared to conventional radiotherapy. Jpn J Clin Oncol. 2008;38(5):334–8.

Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7(6):467–71.

Parekh A, Dholakia AD, Zabranksy DJ, et al. Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: Role of fractionation and treatment volume. Adv Radiat Oncol. 2018;3(1):8–15.

Bray FN, Simmons BJ, Wolfson AH, Nouri K. Acute and chronic cutaneous reactions to ionizing radiation therapy. Dermatol Ther (Heidelb). 2016;6(2):185–206.

Donovan EM, Bleackley NJ, Evans PM, Reise SF. Dose-position and dose-volume histogram analysis of standard wedged and intensity modulated treatments in breast radiotherapy. Br J Radiol. 2002;75:967–73.

Donovan E, Bleakley N, Denholm E, Evans P, Gothard L, Hanson J, et al. Randomised trial of standard 2D radiotherapy ( RT ) versus intensity modulated radiotherapy ( IMRT ) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82:254–64.

Rose F De, Fogliata A, Franceschini D, Iftode C, Navarria P, Comito T, et al. Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy : A prospective evaluation of a case series and review of the literature. The Breast. 2018;42:31–7.


Full Text: PDF

DOI: 10.33371/ijoc.v14i4.741

Article Metrics

Abstract view : 26 times
PDF - 23 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.